NeVap, Inc. VAP is a condition that leads to increased morbidity and mortality in mechanically ventilated patients, occurring when secretions from the oropharynx or stomach are aspirated into the lower respiratory track. These bacteria-rich secretions can pool in the oropharynx or subglottic space above the endotracheal tube cuff.

NeVap's solution involves the removal of these secretions as a strategy to reduce VAP. Through multiple randomized controlled studies and subsequent meta-analyses, NeVap's approach of subglottic suctioning has shown promising results in reducing VAP incidence by 40-67%. Not only does it significantly decrease VAP, but it also leads to secondary outcomes such as reduced antibiotic exposure, delayed onset of VAP, decreased length of mechanical ventilation, and decreased length of ICU stay.

Recognizing the limitations of current devices, NeVap aims to overcome the shortcomings of commercial subglottic suction endotracheal tubes, such as high blockage rates, low fluid removal, and inadequate blood evacuation. Their innovative and improved medical devices aim to enhance the clinical performance and outcomes for ventilated patients